Literature DB >> 22111836

The critical role of vascular endothelial growth factor in tumor angiogenesis.

A Amini1, S Masoumi Moghaddam, D L Morris, M H Pourgholami.   

Abstract

Angiogenesis is the formation of new blood vessels from the pre-existing vasculature. Besides its role in normal physiology, angiogenesis is significantly involved in many pathological conditions, including inflammation, cardiovascular diseases and cancer. Numerous studies have been undertaken in the area of tumor angiogenesis. It is known that pathological angiogenesis is necessary for tumors to proceed from avascular, dormant stage to vascular, sprouting stage and also contributes to their later invasion and metastasis. Playing a central role in tumor angiogenesis, vascular endothelial growth factor is considered as a key target in therapeutic approaches. This article aims to review the critical role of VEGF in tumor angiogenesis and the importance of VEGF-targeted strategies in cancer treatment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22111836     DOI: 10.2174/156800912798888956

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  26 in total

1.  Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.

Authors:  Chia-Jui Yen; Masatoshi Kudo; Ho-Yeong Lim; Chih-Hung Hsu; Arndt Vogel; Giovanni Brandi; Rebecca Cheng; Ioana Simona Nitu; Paolo Abada; Yanzhi Hsu; Andrew X Zhu; Yoon-Koo Kang
Journal:  Liver Cancer       Date:  2020-05-05       Impact factor: 11.740

2.  Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trial.

Authors:  Masatoshi Kudo; Etsuro Hatano; Shinichi Ohkawa; Hirofumi Fujii; Akihide Masumoto; Junji Furuse; Yoshiyuki Wada; Hiroshi Ishii; Shuntaro Obi; Shuichi Kaneko; Seiji Kawazoe; Osamu Yokosuka; Masafumi Ikeda; Katsuaki Ukai; Sojiro Morita; Akihito Tsuji; Toshihiro Kudo; Mitsuo Shimada; Yukio Osaki; Ryosuke Tateishi; Gen Sugiyama; Paolo Benjamin Abada; Ling Yang; Takuji Okusaka; Andrew Xiuxuan Zhu
Journal:  J Gastroenterol       Date:  2016-08-22       Impact factor: 7.527

3.  The pro-migration and anti-apoptosis effects of HMGA2 in HUVECs stimulated by hypoxia.

Authors:  Zhu-Lan Cai; Chen Liu; Qi Yao; Qing-We Xie; Tong-Tong Hu; Qing-Qing Wu; Qi-Zhu Tang
Journal:  Cell Cycle       Date:  2020-12-14       Impact factor: 4.534

4.  The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong-A Territory-Wide Cohort Study.

Authors:  Jeffrey Sum-Lung Wong; Yawen Dong; Vikki Tang; Thomas Leung; Cynthia S Y Yeung; Anna Tai; Ada Law; Tracy Shum; Gerry Gin-Wai Kwok; Bryan Cho-Wing Li; Roland Leung; Joanne Chiu; Ka-Wing Ma; Wong-Hoi She; Josephine Tsang; Tan-To Cheung; Thomas Yau
Journal:  Cancers (Basel)       Date:  2021-04-21       Impact factor: 6.639

5.  Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy.

Authors:  Mary Rusckowski; Yuzhen Wang; Francis G Blankenberg; Zoia Levashova; Marina V Backer; Joseph M Backer
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138

Review 6.  Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity.

Authors:  Luqing Zhao; Ann M Bode; Ya Cao; Zigang Dong
Journal:  Carcinogenesis       Date:  2012-07-12       Impact factor: 4.944

7.  Crystal structures of the catalytic domain of human soluble guanylate cyclase.

Authors:  Charles K Allerston; Frank von Delft; Opher Gileadi
Journal:  PLoS One       Date:  2013-03-07       Impact factor: 3.240

8.  Overexpression of miRNA-497 inhibits tumor angiogenesis by targeting VEGFR2.

Authors:  Yingfeng Tu; Li Liu; Dongliang Zhao; Youbin Liu; Xiaowei Ma; Yuhua Fan; Lin Wan; Tao Huang; Zhen Cheng; Baozhong Shen
Journal:  Sci Rep       Date:  2015-09-08       Impact factor: 4.379

9.  Rapid in vitro derivation of endothelium directly from human cancer cells.

Authors:  Jennifer D Elster; Terence F McGuire; Jie Lu; Edward V Prochownik
Journal:  PLoS One       Date:  2013-10-09       Impact factor: 3.240

10.  Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis.

Authors:  Klaus Mross; Martin Büchert; Annette Frost; Michael Medinger; Peter Stopfer; Matus Studeny; Rolf Kaiser
Journal:  BMC Cancer       Date:  2014-07-11       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.